Weight reduction medicine are proving to be tremendous common amongst many employees with job-based medical insurance. However GLP-1 medicines are busting their employers’ budgets, main some companies to rethink their protection.
The share of very giant companies protecting these medicine for weight problems soared to 43% this 12 months, up from 28% final 12 months, in keeping with KFF’s newest annual Employer Well being Advantages Survey, which was launched on Wednesday. These employers, who’ve greater than 5,000 employees, are more likely than their smaller counterparts to supply such a profit.
Amongst companies with between 200 and 999 staffers, solely 16% present protection of medicine for weight reduction this 12 months, the identical as final 12 months, in keeping with KFF, a nonpartisan well being coverage analysis group.
GLP-1 medicine, which deal with diabetes, weight problems and sure different situations, have been in nice demand since they got here available on the market a couple of years in the past as a result of they assist sufferers shed kilos. Whereas employers usually cowl the medicines for diabetes, fewer of them achieve this for weight reduction, partly due to the medicine’ excessive costs — which have additionally restricted Individuals’ entry to them. The checklist value of Wegovy, as an example, is about $1,350 for a month’s provide, although reductions can be found.
Employers, nevertheless, acknowledge that protecting the medicines for weight reduction is a beneficial profit to draw and retain gifted staffers. Notably, even amongst companies that don’t achieve this, almost half stated the profit is “crucial” or “necessary” for worker satisfaction. Greater than 36 million folks with job-based insurance coverage have a physique mass index that might medically qualify them for a GLP-1 drug.
“Giant employers know these new high-priced weight-loss medicine are an necessary profit for his or her employees, however their prices typically exceed their expectations,” Gary Claxton, KFF senior vp, stated in an announcement. “It’s not a shock that some are rethinking entry to the medicine for weight reduction.”
Prices are larger than forecast as a result of extra employees are profiting from the profit, KFF discovered. Practically 60% of enormous companies stated utilization of the medicines for weight reduction is larger than they predicted, whereas two-thirds of such employers stated the affect on their prescription drug spending was “vital.”
One employer KFF surveyed discovered that it spent extra on GLP-1 medicines than every other drug this 12 months, up from 32nd place final 12 months.
A big retailer informed KFF, “Earlier than we knew it, we spent half one million {dollars} and we’re projected to go as much as $1.2 million the next 12 months.”
The excessive prices of GLP-1 medicine have lengthy been a supply of frustration for a lot of Individuals. President Donald Trump set off a kerfuffle final week when he stated that the medicines would quickly be out there for $150, prompting Mehmet Oz, the Facilities for Medicare and Medicaid Companies administrator, to step in and say negotiations are ongoing.
Many employers informed KFF they have been taking a look at lowering protection of the medicine by means of steps reminiscent of limiting eligibility to these with larger physique mass indexes or requiring employees to take part in weight administration packages.
“You must have a coach, after which you may solely keep on it for a sure period of time earlier than you must get reevaluated,” one giant producer informed KFF.
Different companies informed KFF they’ve determined to drop the profit for weight reduction.
Nonetheless, employers will possible must rethink their protection once more in coming years, particularly as extra employees demand protection, and the medicine are authorised for much more medical situations. Plus, costs coming down.
“We’re nonetheless writing the story of what GLP-1 protection appears to be like like in employer plans,” stated Matthew Rae, affiliate director of the Program on the Well being Care Market at KFF.
GLP-1 drug prices – and prescription drug costs normally – are additionally contributing to an increase in premiums.
Annual insurance coverage protection for a household hit $27,000, on common, this 12 months, up 6% from 2024, in keeping with KFF’s survey. Employees contribute $6,850 towards the price, on common, whereas employers decide up the remainder of the tab.
In the meantime, particular person protection topped $9,300, on common, this 12 months, up 5% – with staff shouldering $1,440 of the price and employers paying the remainder.
Over the previous 5 years, the expansion in premiums has been largely consistent with inflation and wage will increase.
However protection for 2026 might be a lot pricier, in keeping with a number of advantages consulting companies. KFF additionally factors to GLP-1 medicines, hospital costs and tariffs as elements that might push up premiums and out-of-pocket prices for employees subsequent 12 months.
“There’s a quiet alarm bell going off,” Drew Altman, KFF’s CEO, stated in an announcement. “Employers don’t have anything new of their arsenal that may deal with many of the drivers of their price will increase, and that might effectively lead to a rise in deductibles and different types of worker price sharing once more, a technique that neither employers nor staff like however corporations resort to in a pinch to carry down premium will increase.”
Supply hyperlink
#employees #weight #loss #medicine #costing #employers #fortune
About The Author
